Ingrid Desar1,
H. W.M. van Laarhoven1, T. Hambrock2, E. G.W. ter Voert2,
J. J.A. van Asten2, D.J. van Spronsen3, J. O. Barentsz2,
P. F.A. Mulders4, A. Heerschap2, Carla M.L. van Herpen1
1Medical Oncology, Radboud University
Nijmegen Medical Center, Nijmegen, Netherlands; 2Radiology,
Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 3Medical
Oncology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands; 4Urology,
Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Sunitinib
is an oral angiogenesis inhibitor, used as first line treatment in patients
with metastatic renal cell cancer (RCC). A successful antiangiogenic
treatment is expected to result in stabilization of the vasculature, a
reduction in permeability and in interstitial fluid pressure, and the
development of necrosis. This study aims to assess the early vascular effects
of sunitinib in RCC patients with a DCE-MRI and DWI at 3T. Treatment with
sunitinib provokes significant increases in ADC after 3 days, with recurrence
to baseline values at day 10. This is possibly due to the development of
edema and necrosis. In this limited number of patients, no significant
changes in both mean kep and Ktrans values, as well as in the histogram
results were found, although in individual patients some trends indicative
for early vascular effects of sunitinib were observed.